What happens to pharma in Germany when the rules of AMNOG change? In this MAP episode, Dr. Stefan Walzer talks with Prof. Dr. Thomas Hammerschmidt, expert in pharmaceutical management at the Technical University of Applied Sciences Rosenheim (TH Rosenheim), about the latest proposals affecting AMNOG, drug pricing, reimbursement, and market access in Germany.
They discuss dynamic mandatory rebates, tenders for patented drugs, and price-volume agreements, and what these could mean for pharmaceutical companies. Thomas also explains why removing combination rebates and AMNOG guardrails could strengthen incentives for innovation. His key message: companies should prepare for stronger pricing pressure, more uncertainty, and a changing reimbursement landscape, while Germany faces the question of how to contain costs and still reward innovation.